The latest follow-up studies in the SOLO1 ovarian cancer maintenance trial showed that olaparib significantly improved the overall survival (OS) of advanced ovarian cancer patients carrying BRCA1/2 mutations after seven years, marking it the first PARPi shown to provide an OS benefit (43). Here, BRCA1 is linked to ovarian carcinoma.